Johnson & Johnson's 64 consecutive years of dividend increases make it a true Dividend King anchored by a growing healthcare pipeline.
Realty Income's diversified portfolio and monthly dividend streak support dependable income.
Together, J&J offers defensive healthcare stability, while Realty Income adds monthly income for patient investors.
The best dividend stocks are the ones investors can buy and hold forever. Johnson & Johnson (NYSE: JNJ) and Realty Income (NYSE: O) fit that description to a tee. Both companies offer a solid combination of durable businesses, recurring cash flow, and a long history of returning money to shareholders. Even better: One of them is a true Dividend King, a company that has increased its dividend payout for at least the past 50 consecutive years.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
If there's one company that fits the idea of a forever dividend stock, it's Johnson & Johnson. The company has one of the strongest records in the market, recently marking its 64th consecutive year of dividend increases. That makes J&J a true Dividend King, but the more important point is that the dividend is backed by a stable healthcare business that also continues to evolve.
Following its spinoff of Kenvue, which held J&J's personal care products and over-the-counter drugs, the company is now focused on two high-growth areas: innovative medicine and medtech. That gives investors exposure to an aging global population, healthcare spending, and demand for better treatments and medical technologies.
The company also continues to report solid financial results. In the second quarter of 2026, J&J reported broad growth across both major businesses and raised its full-year guidance. Management highlighted its innovation pipeline, including new treatment approvals and developments across oncology, neuroscience, and medical devices.
To expand that pipeline, J&J acquired FireFly Bio, adding a new platform aimed at difficult-to-treat cancers. The deal is another example of how J&J is using acquisitions to find new growth drivers instead of simply relying on existing blockbusters.
For dividend growth investors seeking a long-term hold, J&J offers a diversified healthcare business, consistent demand, and a strategy focused on next-generation products. That's exactly the kind of business that can make sense as a long-term portfolio anchor.
But J&J isn't the only stock built to last.
Realty Income calls itself "The Monthly Dividend Company" and for good reason. As a real estate investment trust, or REIT, the company recently declared its 136th monthly dividend increase. It has built a solid dividend record spanning decades, supported by a business designed to generate predictable rental income.
Perhaps Realty Income's biggest selling point is its huge portfolio of commercial properties. These properties are mainly leased to established retail and industrial companies under long-term net lease agreements, in which tenants bear most property operating costs.
What makes the portfolio attractive is its diversification across tenants, industries, and properties, reducing reliance on any individual customer. Portfolio occupancy remained strong through Q2. This means the income is more stable and predictable, reinforcing the kind of economic moat that supports consistent payouts.
More recently, the company has been building partnerships and expanding into new areas of real estate, including a joint venture targeting hyperscale data centers and a strategic partnership with Apollo. On top of that, it announced a new euro-denominated joint venture with KKR to expand its private capital platform.
Realty Income's diversification gives it a long-term advantage. It can grow by leveraging its scale, relationships, and investment platform to expand its portfolio and tap additional opportunities to increase recurring income.
That combination of income stability and growth potential rounds out the case for owning Realty Income alongside J&J.
For investors looking to build income that can compound for years, J&J and Realty Income both deserve a place in a portfolio.
J&J is the safer, more defensive pick for those who want healthcare stability and a dividend that keeps climbing, almost no matter what the economy does.
On the other hand, Realty Income suits investors who want dependable monthly income and are comfortable with some added real estate exposure.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $385,972!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,416,196!*
Now, it’s worth noting Stock Advisor’s total average return is 951% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 10, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Realty Income. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy.